Rational Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Rational Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-189	Closed	-$14K	–	251
2020 Q3	$14K	Buy	189 +161	+575%	+$16.3K	0.01%	250
2020 Q2	$3K	Buy	+28	New	+$2.78K	﹤0.01%	453
2020 Q1	–	Sell	-63	Closed	-$5K	–	207
2019 Q4	$5K	Sell	63 -144	-70%	-$10.9K	﹤0.01%	482
2019 Q3	$14K	Buy	207 +21	+11%	+$1.62K	0.01%	478
2019 Q2	$16K	Sell	186 -112	-38%	-$9.58K	0.01%	459
2019 Q1	$26K	Buy	298 +289	+3,211%	+$26.8K	0.01%	367
2018 Q4	$1K	Sell	9 -230	-96%	-$21.9K	﹤0.01%	495
2018 Q3	$23K	Buy	239 +235	+5,875%	+$23.5K	0.01%	346
2018 Q2	$0	Buy	+4	New	+$350	﹤0.01%	513

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Rational Advisors's BMRN Position: Q4 2020 in Review

Rational Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2020, closing a stake of 189 shares — an estimated $14K sold.

Rational Advisors first reported a position in BMRN in Q2 2018 and held it in 9 quarters. The position peaked at $26K in Q1 2019. 537 funds tracked by Wall St. Rank hold BMRN as of Q4 2020.

Rational Advisors reported no remaining BioMarin Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
Rational Advisors sold 189 BioMarin Pharmaceuticals shares in Q4 2020, an estimated $14K.
Rational Advisors first reported a position in BioMarin Pharmaceuticals in Q2 2018 and held it in 9 quarters.
Rational Advisors's BioMarin Pharmaceuticals position peaked at $26K in Q1 2019.
537 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2020.

Based on Rational Advisors's 13F filing for Q4 2020, filed 5 Feb 2021.